Gardiquimod
featured

We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 563634

CAS#: 1020412-43-4

Description: Gardiquimod is a TLR7 agonist, inducing the activation of NF-B in HEK293 cells expressing human or mouse TLR7.


Price and Availability

Size Price Shipping out time Quantity
5mg USD 220 2 Weeks
10mg USD 360 2 Weeks
25mg USD 590 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-03-29. Prices are subject to change without notice.

Gardiquimod, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 563634
Name: Gardiquimod
CAS#: 1020412-43-4
Chemical Formula: C17H23N5O
Exact Mass: 313.1903
Molecular Weight: 313.4
Elemental Analysis: C, 65.15; H, 7.40; N, 22.35; O, 5.10


Synonym: Gardiquimod;

IUPAC/Chemical Name: 1-[4-Amino-2-(ethylaminomethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol

InChi Key: FHJATBIERQTCTN-UHFFFAOYSA-N

InChi Code: InChI=1S/C17H23N5O/c1-4-19-9-13-21-14-15(22(13)10-17(2,3)23)11-7-5-6-8-12(11)20-16(14)18/h5-8,19,23H,4,9-10H2,1-3H3,(H2,18,20)

SMILES Code: CC(O)(C)CN1C(CNCC)=NC2=C1C3=CC=CC=C3N=C2N


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.03.00


References

1: Kim S, Kaiser P, Borowska D, Vervelde L. Synergistic effect of co-stimulation of membrane and endosomal TLRs on chicken innate immune responses. Vet Immunol Immunopathol. 2018 May;199:15-21. doi: 10.1016/j.vetimm.2018.03.005. Epub 2018 Mar 19. PubMed PMID: 29678225.

2: Enosi Tuipulotu D, Netzler NE, Lun JH, Mackenzie JM, White PA. TLR7 Agonists Display Potent Antiviral Effects against Norovirus Infection via Innate Stimulation. Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02417-17. doi: 10.1128/AAC.02417-17. Print 2018 May. PubMed PMID: 29530841; PubMed Central PMCID: PMC5923118.

3: Rudra JS, Banasik BN, Milligan GN. A combined carrier-adjuvant system of peptide nanofibers and toll-like receptor agonists potentiates robust CD8+ T cell responses. Vaccine. 2018 Jan 25;36(4):438-441. doi: 10.1016/j.vaccine.2017.12.017. Epub 2017 Dec 14. PubMed PMID: 29248267; PubMed Central PMCID: PMC5769694.

4: Braun RO, Python S, Summerfield A. Porcine B Cell Subset Responses to Toll-like Receptor Ligands. Front Immunol. 2017 Aug 25;8:1044. doi: 10.3389/fimmu.2017.01044. eCollection 2017. PubMed PMID: 28890720; PubMed Central PMCID: PMC5574874.

5: Chi H, Li C, Zhao FS, Zhang L, Ng TB, Jin G, Sha O. Anti-tumor Activity of Toll-Like Receptor 7 Agonists. Front Pharmacol. 2017 May 31;8:304. doi: 10.3389/fphar.2017.00304. eCollection 2017. Review. PubMed PMID: 28620298; PubMed Central PMCID: PMC5450331.

6: Zhu Q, Kanneganti TD. Cutting Edge: Distinct Regulatory Mechanisms Control Proinflammatory Cytokines IL-18 and IL-1β. J Immunol. 2017 Jun 1;198(11):4210-4215. doi: 10.4049/jimmunol.1700352. Epub 2017 May 3. PubMed PMID: 28468974; PubMed Central PMCID: PMC5544497.

7: Guo S, Zhang Y, Wang Z, Yu Y, Wang G. Intraperitoneal gardiquimod protects against hepatotoxicity through inhibition of oxidative stress and inflammation in mice with sepsis. J Biochem Mol Toxicol. 2017 Aug;31(8). doi: 10.1002/jbt.21923. Epub 2017 Apr 19. PubMed PMID: 28422377.

8: Seth A, Lee H, Cho MY, Park C, Korm S, Lee JY, Choi I, Lim YT, Hong KS. Combining vasculature disrupting agent and Toll-like receptor 7/8 agonist for cancer therapy. Oncotarget. 2017 Jan 17;8(3):5371-5381. doi: 10.18632/oncotarget.14260. PubMed PMID: 28036266; PubMed Central PMCID: PMC5354915.

9: Gupta N, Vedi S, Kunimoto DY, Agrawal B, Kumar R. Novel lipopeptides of ESAT-6 induce strong protective immunity against Mycobacterium tuberculosis: Routes of immunization and TLR agonists critically impact vaccine's efficacy. Vaccine. 2016 Nov 4;34(46):5677-5688. doi: 10.1016/j.vaccine.2016.08.075. Epub 2016 Sep 29. PubMed PMID: 27693020.

10: Liu Y, Guo X, Wu L, Yang M, Li Z, Gao Y, Liu S, Zhou G, Zhao J. Lipid rafts promote liver cancer cell proliferation and migration by up-regulation of TLR7 expression. Oncotarget. 2016 Sep 27;7(39):63856-63869. doi: 10.18632/oncotarget.11697. PubMed PMID: 27588480; PubMed Central PMCID: PMC5325409.

11: Nyberg WA, Espinosa A. Imiquimod induces ER stress and Ca(2+) influx independently of TLR7 and TLR8. Biochem Biophys Res Commun. 2016 May 13;473(4):789-794. doi: 10.1016/j.bbrc.2016.03.080. Epub 2016 Mar 19. PubMed PMID: 27003259.

12: Wang F, Jin R, Zou BB, Li L, Cheng FW, Luo X, Geng X, Zhang SQ. Activation of Toll-like receptor 7 regulates the expression of IFN-λ1, p53, PTEN, VEGF, TIMP-1 and MMP-9 in pancreatic cancer cells. Mol Med Rep. 2016 Feb;13(2):1807-12. doi: 10.3892/mmr.2015.4730. Epub 2015 Dec 29. PubMed PMID: 26718740.

13: Zhou Z, Yu X, Zhang J, Tian Z, Zhang C. TLR7/8 agonists promote NK-DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma. Cancer Lett. 2015 Dec 28;369(2):298-306. doi: 10.1016/j.canlet.2015.09.017. Epub 2015 Oct 9. PubMed PMID: 26433159.

14: Zou BB, Wang F, Li L, Cheng FW, Jin R, Luo X, Zhu LX, Geng X, Zhang SQ. Activation of Toll-like receptor 7 inhibits the proliferation and migration, and induces the apoptosis of pancreatic cancer cells. Mol Med Rep. 2015 Oct;12(4):6079-85. doi: 10.3892/mmr.2015.4130. Epub 2015 Jul 28. PubMed PMID: 26238718.

15: Lee HJ, Kim KC, Han JA, Choi SS, Jung YJ. The early induction of suppressor of cytokine signaling 1 and the downregulation of toll-like receptors 7 and 9 induce tolerance in costimulated macrophages. Mol Cells. 2015 Jan 31;38(1):26-32. doi: 10.14348/molcells.2015.2136. Epub 2014 Dec 15. PubMed PMID: 25518931; PubMed Central PMCID: PMC4314129.

16: Bikker A, Kruize AA, van der Wurff-Jacobs KM, Peters RP, Kleinjan M, Redegeld F, de Jager W, Lafeber FP, van Roon JA. Interleukin-7 and Toll-like receptor 7 induce synergistic B cell and T cell activation. PLoS One. 2014 Apr 16;9(4):e94756. doi: 10.1371/journal.pone.0094756. eCollection 2014. PubMed PMID: 24740301; PubMed Central PMCID: PMC3989236.

17: Li L, Cheng FW, Wang F, Jia B, Luo X, Zhang SQ. The activation of TLR7 regulates the expression of VEGF, TIMP1, MMP2, IL-6, and IL-15 in Hela cells. Mol Cell Biochem. 2014 Apr;389(1-2):43-9. doi: 10.1007/s11010-013-1925-y. Epub 2013 Dec 18. PubMed PMID: 24347177.

18: Quan FS, Ko EJ, Kwon YM, Joo KH, Compans RW, Kang SM. Mucosal adjuvants for influenza virus-like particle vaccine. Viral Immunol. 2013 Dec;26(6):385-95. doi: 10.1089/vim.2013.0013. Epub 2013 Nov 16. PubMed PMID: 24236855; PubMed Central PMCID: PMC3868302.

19: Jia B, Luo X, Cheng FW, Li L, Hu DJ, Wang F, Zhang SQ. Gardiquimod inhibits the expression of calcium-induced differentiation markers in HaCaT cells. Mol Biol Rep. 2013 Nov;40(11):6363-9. doi: 10.1007/s11033-013-2750-9. Epub 2013 Sep 22. PubMed PMID: 24057248.

20: Oumata N, Nguyen PH, Beringue V, Soubigou F, Pang Y, Desban N, Massacrier C, Morel Y, Paturel C, Contesse MA, Bouaziz S, Sanyal S, Galons H, Blondel M, Voisset C. The toll-like receptor agonist imiquimod is active against prions. PLoS One. 2013 Aug 16;8(8):e72112. doi: 10.1371/journal.pone.0072112. eCollection 2013. PubMed PMID: 23977222; PubMed Central PMCID: PMC3745460.